622 related articles for article (PubMed ID: 28267530)
21. Comparison of
Sawicki LM; Kirchner J; Grueneisen J; Ruhlmann V; Aktas B; Schaarschmidt BM; Forsting M; Herrmann K; Antoch G; Umutlu L
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):622-629. PubMed ID: 29164299
[TBL] [Abstract][Full Text] [Related]
22. 18F-FDG PET in the management of endometrial cancer.
Chao A; Chang TC; Ng KK; Hsueh S; Huang HJ; Chou HH; Tsai CS; Yen TC; Wu TI; Lai CH
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):36-44. PubMed ID: 16167154
[TBL] [Abstract][Full Text] [Related]
23. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
[TBL] [Abstract][Full Text] [Related]
24. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
25. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
26. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
[TBL] [Abstract][Full Text] [Related]
27. What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?
Botsikas D; Bagetakos I; Picarra M; Da Cunha Afonso Barisits AC; Boudabbous S; Montet X; Lam GT; Mainta I; Kalovidouri A; Becker M
Eur Radiol; 2019 Apr; 29(4):1787-1798. PubMed ID: 30267154
[TBL] [Abstract][Full Text] [Related]
28. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer.
Xin J; Ma Q; Guo Q; Sun H; Zhang S; Liu C; Zhai W
Eur J Radiol; 2016 Apr; 85(4):751-9. PubMed ID: 26971419
[TBL] [Abstract][Full Text] [Related]
29. Comparison of MRI Sequences in Whole-Body PET/MRI for Staging of Patients With High-Risk Prostate Cancer.
Metser U; Chan R; Veit-Haibach P; Ghai S; Tau N
AJR Am J Roentgenol; 2019 Feb; 212(2):377-381. PubMed ID: 30332285
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
31. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
Eur J Radiol; 2010 Feb; 73(2):294-9. PubMed ID: 19181468
[TBL] [Abstract][Full Text] [Related]
32. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
[TBL] [Abstract][Full Text] [Related]
33. Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer: A Comparison With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging.
Grueneisen J; Nagarajah J; Buchbender C; Hoffmann O; Schaarschmidt BM; Poeppel T; Forsting M; Quick HH; Umutlu L; Kinner S
Invest Radiol; 2015 Aug; 50(8):505-13. PubMed ID: 26115367
[TBL] [Abstract][Full Text] [Related]
34. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.
Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S
J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.
Schmidt GP; Baur-Melnyk A; Haug A; Heinemann V; Bauerfeind I; Reiser MF; Schoenberg SO
Eur J Radiol; 2008 Jan; 65(1):47-58. PubMed ID: 18082989
[TBL] [Abstract][Full Text] [Related]
36. Performing clinical 18F-FDG-PET/MRI of the mediastinum optimising a dedicated, patient-friendly protocol.
Peerlings J; Paulis L; Mitea C; Bakers F; Berbée M; Wierts R; Vöö S; Wildberger J; Hoffmann A; Lambin P; Mottaghy F
Nucl Med Commun; 2019 Aug; 40(8):815-826. PubMed ID: 31169592
[TBL] [Abstract][Full Text] [Related]
37. Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
Ohno Y; Yui M; Aoyagi K; Kishida Y; Seki S; Koyama H; Yoshikawa T
AJR Am J Roentgenol; 2019 Feb; 212(2):311-319. PubMed ID: 30512992
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot study.
Schwenzer NF; Schraml C; Müller M; Brendle C; Sauter A; Spengler W; Pfannenberg AC; Claussen CD; Schmidt H
Radiology; 2012 Aug; 264(2):551-8. PubMed ID: 22653189
[TBL] [Abstract][Full Text] [Related]
39. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
40. Comparison of
Sarabhai T; Schaarschmidt BM; Wetter A; Kirchner J; Aktas B; Forsting M; Ruhlmann V; Herrmann K; Umutlu L; Grueneisen J
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):67-76. PubMed ID: 28840302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]